Kavita Desai Selected Research

GEM231

3/2006	A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
9/2003	A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kavita Desai Research Topics

Disease

4	Neoplasms (Cancer) 11/2008 - 09/2003
2	Fatigue 03/2006 - 09/2003
1	Fetal Weight 01/2016
1	Infertility (Sterility) 01/2016
1	Fetal Growth Retardation (Intrauterine Growth Retardation) 01/2016
1	Oligohydramnios 01/2016
1	Leiomyoma (Uterine Fibroids) 01/2015
1	Gaucher Disease (Gaucher's Disease) 01/2009
1	Hypoxia (Hypoxemia) 11/2008
1	Breast Neoplasms (Breast Cancer) 06/2007
1	Febrile Neutropenia 03/2006

Drug/Important Bio-Agent (IBA)

2	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 03/2006 - 09/2003
2	GEM231IBA 03/2006 - 09/2003
1	Sildenafil Citrate (Viagra)FDA Link 01/2016
1	ProdrugsIBA 11/2008
1	Topoisomerase II InhibitorsIBA 11/2008
1	AQ4NIBA 11/2008
1	EsterasesIBA 06/2007
1	Irinotecan (Camptosar)FDA LinkGeneric 06/2007
1	Capecitabine (Xeloda)FDA Link 06/2007
1	Antisense OligonucleotidesIBA 03/2006
1	Transaminases (Aminotransferases)IBA 03/2006
1	Docetaxel (Taxotere)FDA Link 03/2006
1	OligonucleotidesIBA 09/2003

Therapy/Procedure

2	Therapeutics 01/2009 - 03/2006
2	Drug Therapy (Chemotherapy) 06/2007 - 03/2006
1	Aftercare (After-Treatment) 01/2016
1	Hysterectomy 01/2015